Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 terminated deal — weigh against the wins.
1 vehicle on file, newest listing first
none appears on more than one
Allen C. Wang is a retired corporate law partner and independent board director with over 25 years of experience in law and finance. He served as an independent board director, Chair of the Compensation Committee, and member of the Audit Committee for Iris Acquisition Corp II, a USD 276 million special purpose acquisition company listed on the Nasdaq Capital Market, until his retirement from the board in July 2025. In this role, he leveraged his deep expertise in capital markets, public company representation, and mergers and acquisitions to guide the SPAC's strategic initiatives and governance.
Throughout his distinguished legal career, Mr. Wang was a partner in the Hong Kong office of Latham & Watkins, where he retired from the partnership in June 2025. His practice focused on domestic and international capital markets transactions, including high-yield bonds, IPOs, investment-grade debt, and convertibles, as well as mergers, acquisitions, and restructurings across industries such as life sciences, technology, media, gaming, and financial institutions. He advised prominent domestic and international companies and investment banks, including Goldman Sachs, Morgan Stanley, Credit Suisse, Bank of America Merrill Lynch, JP Morgan, and Deutsche Bank Securities. Prior to joining Latham & Watkins, he worked as an associate in the general practice group at a leading law firm in New York and as an investment banking associate in the financial institutions group at Morgan Stanley in New York, advising on capital markets and M&A transactions.
Mr. Wang's notable transaction record includes advising the underwriters on Adlai Nortye’s US IPO, the first US IPO to obtain a China Securities Regulation Commission filing, and representing the underwriters on Atour Lifestyle’s initial public offering and subsequent public offering on the Nasdaq. He also advised on H World Group’s US$300 million follow-on offering. Recognized as a leading practitioner by Chambers Greater China, Legal 500 Asia Pacific, and IFLR1000, he was noted for his expertise in advising Chinese clients on US listings and ADS issuances, with sources describing him as a "go-to for tricky US issues" and a "very strong transaction manager."
Mr. Wang holds a BA from Yale University, graduating summa cum laude and Phi Beta Kappa in 1992, a JD from Harvard Law School, graduating magna cum laude in 1997, and an MBA from Oxford University in 1998, where he was a Fulbright Scholar. Based in Hong Kong, his extensive cross-border transactional experience and public company governance background have made him a valuable asset to the boards and corporate clients he serves.
This record carries no SEC CIK. The name was read out of filing prose, so each role above is true of the filing it cites — but two people who share a name would share this page, and we cannot tell you that they do not. That is why the network below the career is withheld here: a recurrence needs an identity, and a name is not one.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 6 institutional-holder rows on these vehicles, under 5 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.